Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost

Journal of Glaucoma

Volumn 21, Issue 1, 2012, Pages 60-64

  Aihara, Makoto ^a   Otani, Shin Ichiro ^b   Kozaki, Jun ^c   Unoki, Kazuhiko ^d   Takeuchi, Masamitsu ^e   Minami, Keiichiro ^b   Miyata, Kazunori ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b Miyata Eye Hospital Miyazaki   (Japan)

^c Kozaki Eye Clinic   (Japan)

^d Unoki Eye Clinic   (Japan)

^e Takeuchi Eye Clinic   (Japan)

Author keywords

benzalkonium chloride; glaucoma; intraocular pressure; latanoprost; ocular surface; Travoprost

Indexed keywords

BENZALKONIUM CHLORIDE; LATANOPROST; TRAVOPROST;

ADULT; AGED; ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE BURNING; EYE IRRITATION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KERATOPATHY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; OPEN STUDY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SUPERFICIAL PUNCTATE KERATOPATHY; TONOMETRY; VISUAL DISORDER;

AGED; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CLOPROSTENOL; CONJUNCTIVAL DISEASES; CORNEA; CORNEAL DISEASES; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 84855462450     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181fc8129     Document Type: Article

References (25)

1. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341-349. (Pubitemid 47056287)
2. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucomamedication. Br J Ophthalmol. 2002;86:418-423. (Pubitemid 34293291)
3. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17: 350-355.
4. Guenoun JM, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:2444-2450. (Pubitemid 43119492)
5. Cha SH, Lee JS, Oum BS, et al. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Experiment Ophthalmol. 2004;32:180-184.
6. De Saint Jean M, Debbasch C, Brignole F, et al. Toxicity ofpreserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20: 85-94. (Pubitemid 30099159)
7. Burstein NL. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol. 1980;25:15-30. (Pubitemid 10087456)
8. Brasnu E, Brignole-Baudouin F, Riancho L, et al. In vitro effects of preservative-free tafluprost and preserved latano-prost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008;33:303-312. (Pubitemid 351507760)
9. Baudouin C, Riancho L, Warnet JM, et al. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123-4128. (Pubitemid 351261038)
10. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006;23:511-519.
11. Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291-295.
12. Henry JC, Peace JH, Stewart JA, et al. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2:613-621.
13. Miyata K, Amano S, Sawa M, et al. A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch Ophthal-mol. 2003;121:1537-1539. (Pubitemid 37392355)
14. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized con-trolled clinical trials. J Glaucoma. 2008;17:667-673.
15. Van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthal-mology. 2005;112:1177-1185. (Pubitemid 40916921)
16. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sof Zia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339-343. (Pubitemid 351440870)
17. Rios JL, Boechat JL, Gioda A, et al. Symptoms prevalence among office workers of a sealed versus a non-sealed building: associationstoindoorairquality. Environ Int. 2009;35:1136-1141.
18. Su SB, Wang BJ, Tai C, et al. Higher prevalence of dry symptoms in skin, eyes, nose and throat among workers in clean rooms with moderate humidity. J Occup Health. 2009;51:364-369.
19. Honrubia F, Garcia-Sanchez J, Polo V, et al. Conjunctival hyperaemia with the use of latanoprost versus other prosta-glandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009;93:316-321.
20. Stewart WC, Kolker AE, Stewart JA, et al. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol. 2003;135:314-320. (Pubitemid 36279517)
21. Kumar RS, Istiantoro VW, Hoh ST, et al. Efficacy and safety of a systematic switch from latanoprost to travoprost in patients with glaucoma. J Glaucoma. 2007;16:606-609. (Pubitemid 350307612)
22. Astin M, Stjernschantz J, Selen G. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994;59:401-407.
23. Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008;17:217-222. (Pubitemid 351543547)
24. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16:98-103. (Pubitemid 46114782)
25. Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21: 221-232.